metformin butyric acid salt | 1261952-47-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: metformin butyric acid salt
• 英文别名: Butanoic acid;3-(diaminomethylidene)-1,1-dimethylguanidine
• CAS: 1261952-47-9
• 化学式: C₄H₈O₂*C₄H₁₁N₅
• 分子量: 217.271
• InChiKey: CBFPQMMNHFGKHA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.37
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  129
• 氢给体数：
  4
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  二甲双胍 、 丁酸 以 丙酮 为溶剂， 反应 2.0h， 以98%的产率得到metformin butyric acid salt
  参考文献：
  名称：

  BUTYRIC ACID SALT OF N,N-DIMETHYL IMIDOCARBON IMIDIC DIAMIDE, METHOD OF PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS CONTAINING SAME

  摘要：

  本发明提供了丁酸盐酸二甲双胍、其制备方法，以及含有该盐酸二甲双胍的药物组合物和药物组合物。根据本发明，盐酸二甲双胍丁酸盐具有比盐酸二甲双胍更优异的药理效果，并且可以通过比盐酸二甲双胍更少的用量实现治疗目的。此外，盐酸二甲双胍丁酸盐在制剂的加工过程中具有优异的物理化学性质，如溶解度、稳定性、吸湿性和吸附防止性能，因此可以作为盐酸二甲双胍的药用可接受盐酸。

  公开号：

  US20120135952A1

文献信息

• METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS
  申请人：Kura Oncology, Inc.

  公开号：EP3873469A2

  公开（公告）日：2021-09-08
• [EN] BUTYRIC ACID SALT OF N,N-DIMETHYL IMIDOCARBON IMIDIC DIAMIDE, METHOD OF PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS CONTAINING SAME<br/>[FR] SEL D'ACIDE BUTYRIQUE DE N,N-DIMÉTHYL DIAMIDE IMIDOCARBONIMIDIQUE, SON PROCÉDÉ DE PRÉPARATION, AINSI QUE COMPOSITIONS ET COMBINAISONS PHARMACEUTIQUES LE CONTENANT
  申请人：HANALL BIOPHARMA CO LTD

  公开号：WO2011008054A2

  公开（公告）日：2011-01-20

  본 발명은 메트포르민 부틸산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 복합제제를 제공한다. 본 발명의 메트포르민 부틸산염은 메트포르민 염산염에 비해 약리학적 효과가 우수할 뿐만 아니라 메트포르민 염산염보다 적은 용량을 투여하여 치료목적을 달성할 수 있다. 또한 용해도, 안정성, 흡습성, 부착방지특성 같은 제형으로서의 가공성 등의 물리화학적 성질이 우수하여 메트포르민의 약제학적으로 허용되는 염으로써 유용하게 이용될 수 있다.
• [EN] A COMBINATION COMPRISING GRANULOCYTE COLONY STIMULATING FACTOR<br/>[FR] COMBINAISON COMPRENANT UN FACTEUR DE STIMULATION DES COLONIES DE GRANULOCYTES
  申请人：ARVEN ILAC SANAYI VE TICARET ANONIM SIRKETI

  公开号：WO2020139300A2

  公开（公告）日：2020-07-02

  The present invention relates to a pharmaceutical combination comprising granulocyte-colony stimulating factor (G-CSF) and a biguanide compound for treating a patient with cancer with a targeted therapy in combination with chemotherapies.
• BUTYRIC ACID SALT OF N,N-DIMETHYL IMIDOCARBON IMIDIC DIAMIDE, METHOD OF PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS CONTAINING SAME
  申请人：Kim Sung Wuk

  公开号：US20120135952A1

  公开（公告）日：2012-05-31

  The present invention provides metformin butyric acid salt, a method of preparing the same, and pharmaceutical compositions and combinations containing the same. The metformin butyric acid salt according to the present invention has an excellent pharmacological effect as compared with metformin hydrochloride and is capable of achieving a therapeutic purpose by administering an amount less than metformin hydrochloride. Furthermore, the metformin butyric acid salt has excellent physicochemical properties, such as solubility, stability, hygroscopicity and adsorption preventing property, in processibility of formulations and thereby is capable of being usefully utilized as a pharmaceutically acceptable salt of the metformin.

  本发明提供了丁酸盐酸二甲双胍、其制备方法，以及含有该盐酸二甲双胍的药物组合物和药物组合物。根据本发明，盐酸二甲双胍丁酸盐具有比盐酸二甲双胍更优异的药理效果，并且可以通过比盐酸二甲双胍更少的用量实现治疗目的。此外，盐酸二甲双胍丁酸盐在制剂的加工过程中具有优异的物理化学性质，如溶解度、稳定性、吸湿性和吸附防止性能，因此可以作为盐酸二甲双胍的药用可接受盐酸。